Who is the CEO of ValiRx plc?

Dr. Mark Eccleston M.B.A., Ph.D. is a business executive who currently serves as the CEO of ValiRx plc.

What is the Revenue Growth of ValiRx plc?

Revenue growth data for ValiRx plc is currently unavailable.

What is ValiRx plc operating Margin?

ValiRx plc operating margin is -23284.05% which shows how much profit VAL.L earns from each dollar of sales, after subtracting the direct costs tied to generating that revenue.

In which market sector does ValiRx plc operate?

ValiRx plc falls under the Healthcare sector which thrives across multiple industries. It stays competitive through its diverse product lineup, which spans computer hardware, tech gadgets, video streaming services, and cloud computing solutions.

What is ValiRx plc revenue growth?

Revenue growth data for ValiRx plc is currently unavailable.

ValiRx plc

VAL.L•LSE

HealthcareBiotechnology

$0.53

$0.02(4.57%)

ValiRx plc (VAL.L) Stock Overview

Explore ValiRx plc’s financial performance, market position, analyst ratings, and future outlook.

Stats data is not available for VAL.LStats details for VAL.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Analyst Recommendations data is not available for VAL.LAnalyst Recommendations details for VAL.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a small molecule that has completed Phase I/II trials for the treatment of prostate cancer and other hormone associated solid tumours comprising breast and ovarian cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of women with endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Hatfield, the United Kingdom.

CEO

Dr. Mark Eccleston M.B.A., Ph.D.

Employees

Headquarters

Stonebridge House, Hatfield

Founded

2002